by | Mar 2, 2022 | Lim, Kian-Huat, Liu, Yongjian, Zhang, Xiaohui
— Disease indication –
Drug format – Combination containing radiolabeled copper nanocluster, small molecule, and peptide
Drug class – First-in-class
Target – CCR2, the receptor for CCL2
Mode of action – The ECL1i peptide is conjugated to a copper nanocluster loaded…
by | Feb 23, 2022 | Cui, Jianmin
— Disease indication – Long QT Syndrome (resulting in ventricular arrhythmia, epilepsy, deafness)
Drug format – Small molecule
Drug class – Lead compounds are repurposed drugs
Research stage and preliminary data – Based on in silico screening of KCNQ, the researchers selecte…
by | Feb 18, 2022 | Kreple, Collin, Miller, Timothy, Nielsen, Susan, Racette, Brad
— Technology Description
Researchers in Brad Racette and Tim Miller’s labs at Washington University have developed a therapeutic strategy for treating ALS by using statins to lower LDL. Statins were successful at prolonging both survival and time with a normal gait.
The researchers identif…
by | Feb 16, 2022 | Azab, Abdel Kareem, Federico, Cinzia
— Technology Description
Researchers in Prof. Kareem Azab’s laboratory have developed a liposome drug delivery vehicle to improve efficacy and reduce side effects of multiple myeloma treatment. This system is designed to target compounds to the bone marrow microenvironment (BMME) and simultane…
by | Jan 13, 2022 | DeSelm, Carl
— Technology Description
Researchers at Washington University in St. Louis have developed a genetic method to produce chimeric antigen receptor dendritic cells (CAR-DCs) for the treatment of solid tumors. The team generated a CAR that drives differentiation of cDC1s and mediates tumor-specific uptak…